Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Clopidogrel is a prescription P2Y12 platelet inhibitor used to reduce the risk of heart attack and stroke in selected cardiovascular conditions. It is used for acute coronary syndrome and for patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease. Common tablet strengths include 75 mg and 300 mg.
read more about clopidogrel ...Clopidogrel must be converted by CYP enzymes, principally CYP2C19, to an active metabolite. That metabolite binds irreversibly to platelet P2Y12 ADP receptors and blocks downstream platelet activation and aggregation. The effect persists for the life of the affected platelet.
Clopidogrel is used in non-ST elevation and ST elevation acute coronary syndromes to reduce myocardial infarction and stroke risk. It is also used in patients with a recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease. Treatment choice depends on the cardiovascular condition, bleeding risk, and CYP2C19 function.
Acute coronary syndrome treatment starts with a single 300 mg oral loading dose followed by 75 mg once daily. Patients with a recent myocardial infarction, recent stroke, or established peripheral arterial disease take 75 mg once daily without a loading dose. Premature discontinuation raises the risk of cardiovascular events.
Clopidogrel carries a boxed warning for reduced antiplatelet activity in patients with two loss-of-function CYP2C19 alleles. Bleeding is the most common serious adverse reaction. Other concerns include thrombotic thrombocytopenic purpura and hypersensitivity. Active pathological bleeding is a contraindication, and omeprazole or esomeprazole can reduce clopidogrel antiplatelet activity.
Yes. Clopidogrel is a P2Y12 inhibitor that reduces platelet activation and aggregation.
The usual maintenance dose is 75 mg once daily.
Yes. The boxed warning concerns reduced antiplatelet activity in CYP2C19 poor metabolizers with two loss-of-function alleles.
Yes. Bleeding, including serious or fatal bleeding, is a major risk of clopidogrel treatment.
Clopidogrel. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a601040.html. Date Accessed September 23, 2026.
Clopidogrel. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Clopidogrel. Date Accessed September 23, 2026.
Clopidogrel. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470539/. Date Accessed September 23, 2026.
DailyMed - CLOPIDOGREL tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c03a895c-2d74-4d7f-891f-b752ce409b68. Date Accessed September 23, 2026.
DailyMed - PLAVIX (clopidogrel) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227. Date Accessed September 23, 2026.